Surrogates, substudies, and real clinical end points in trials of drug-eluting stents

J Am Coll Cardiol. 2005 Apr 19;45(8):1206-12. doi: 10.1016/j.jacc.2005.01.005.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Clinical Trials, Phase IV as Topic
  • Coronary Disease / therapy*
  • Coronary Restenosis / prevention & control*
  • Humans
  • Paclitaxel / administration & dosage*
  • Randomized Controlled Trials as Topic
  • Research Design
  • Stents*

Substances

  • Antineoplastic Agents
  • Paclitaxel